Evaluation of polymeric adjuvants associated with cadidate vaccine strain Brucella ovis ∆abcBA in a murine model of Brucella ovis infection
DOI:
https://doi.org/10.12834/VetIt.3016.31419.2Keywords:
ABC transporter, alginate, chitosan, immune response, mice model, ovine brucellosisAbstract
Brucellosis is an infectious disease caused by facultative intracellular Gram-negative bacteria, of great importance in animal and human health. An ideal vaccine against brucellosis should induce protection, not cause disease in animals or humans, and not interfere with serological diagnosis. Vaccine adjuvants can improve the immune response, leading to a more intense and prolonged protection, improving its effectiveness. The Brucella ovis ΔabcBA strain encapsulated in alginate provides an experimental vaccine formulation that protects against Brucella spp. infection. However, the investigation of other polymers such as adjuvants is important for optimizing the efficiency of the candidate vaccine B. ovis ∆abcBA. Therefore, this study aimed to evaluate the vaccine potential of the B. ovis ∆abcBA associated with different polymeric adjuvants in mice challenged with B. ovis. We observed that B. ovis ∆abcBA encapsulated by alginate with chitosan, but not copolymer Poloxamer 407, resulted in the lowest bacterial recovery in both the spleen and liver of challenged animals compared to non-vaccinated mice. While copolymer Poloxamer 407 did not induce significant humoral immune response, the alginate and chitosan vaccine formulation induced higher levels of Immunoglobulin G, with an increase in the IgG2b subclass, indicating a Th1 type of response, which is known to play a critical role in controlling infections by intracellular agents.References
Abkar M., Alamianb S. & Sattarahmady N.A. 2019. Comparison between adjuvant and delivering functions of calcium phosphate, aluminum hydroxide and chitosan nanoparticles, using a model protein of Brucella melitensis Omp31. Immunol Lett, 207, 28 – 35. https://doi.org/10.1016/j.imlet.2019.01.010.
Abkar M., Lotfi A.S., Amani J., Eskandari K., Ramandi M.F., Salimian J. Brujeni G.N., Alamian S., Kamali M. & Koushki H. 2015. Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization. Vet Res Commun, 39, 4, 217-228. https://doi.org/10.1007/s11259-015-9645-2 .
Arenas-Gamboa M., Ficht T.A., Kahl-McDonagh M.M. Gomez G. & Rice-Ficht A.C. 2009. The Brucella abortus S19 ∆vjbR live candidate is safer than S19 and confers protection against wild-type vaccine challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect Immun, 77, 877 - 884. https://doi.org/10.1128/iai.01017-08.
Bobbala S., Tamboli V., McDowell A., Mitra A.K. & Hook S. 2016. Novel injectable pentablock copolymer based thermoresponsive hydrogels for sustained release vaccines. AAPS J, 18, 1, 261 - 269. https://doi.org/10.1208/s12248-015-9843-4.
Brunner R., Jensen-Jarolim E. & Schöll I.P. 2010. The ABC of clinical and experimental adjuvants - a brief overview. Immunol Lett, 128, 1, 29 – 35. https://dx.doi.org/10.1016%2Fj.imlet.2009.10.005.
Burgess G.W. 1982. Ovine contagious epididimytis: a review. Vet Microbiol, 7, 551-575. https://doi.org/10.1016/0378-1135(82)90049-9.
Carvalho Júnior C.A., Moustacas V.S., Xavier M.N., Costa E.A., Costa L.F., Silva T.M.A., Paixão T.A., Borges A.M., Gouveia A.M.G. & Santos R.L. 2012. Andrological, pathologic, morphometric, and altrasonographic findings in rams experimentally infected with Brucella ovis. Small Rumin Res, 102, 213-222. https://doi.org/10.1590/1678-5150-PVB-6481.
Carvalho T.F., Haddad J.P.A., Paixão T.A. & Santos R.L. 2016. Meta-analysis and advancement of brucellosis vaccinology. Plos One, 11, 11, e0166582. https://doi.org/10.1371/journal.pone.0166582.
Carvalho T.F., Haddad J.P.A., Paixão T.A. & Santos R.L. 2020 (a). Meta-analysis of brucellosis vaccinology in natural hosts. Pesq Vet Bras, 40, 8, 604-613. https://doi.org/10.1590/1678-5150-PVB-6651.
Carvalho T.P., Ribeiro N.Q., Mol J.P.S. Costa F.B., Eckstein E., Paula N.F., Paixão T.A. & Santos R.L. 2020 (b). Pathogenic potential of Brucella ovis field isolates with different genotypic profile and protection provided by the vaccine strain B. ovis ΔabcBA against B. ovis field isolates in mice. Pesq Vet Bras, 40, 2, 88–96. https://doi.org/10.1590/1678-5150-PVB-6481.
Corbel M.J. 2006. Food and Agriculture Organization of the United Nations, World Health Organization & World Organization for Animal Health. Brucellosis in humans and animals. World Health Organization. 2006. https://apps.who.int/iris/handle/10665/43597.
Costa L.F, Cabello A.L., Batista D.F.A., Chaki S.P., Figueiredo P., Paixão T.A., Rice-Ficht A.C., Ficht T.A. & Santos R.L. 2020. The candidate vaccine strain Brucella ovis ΔabcBA is protective against Brucella melitensis infection in mice. Microbiol Immunol, 11, 64, 730 – 736. https://doi.org/10.1111/1348-0421.12850.
Dumkliang E., Pamornpathomkul B., Patrojanasophon P., Ngawhirunpat T., Rojanarata T., Yoksan S. & Opanasopit, P. et al. 2021. Feasibility of chitosan-based nanoparticles approach for intranasal immunisation of live attenuated japanese encephalitis vaccine. Int J Biol Macromol, 183, 1096 – 1105. https://doi.org/10.1016/j.ijbiomac.2021.05.050.
Dumortier G., Grossiord J.L., Agnely F. & Chaumeil J.C. 2006. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res, 23, 12, 2709–2728. https://doi.org/10.1007/s11095-006-9104-4.
Eckstein C., Mol J.P.S., Costa F.B., Nunes P.P., Lima P.A., Melo M.M., Carvalho T.P., Santos D.O., Silva M.F., Carvalho T.F., Costa L.F., Melo Júnior O.A.O., Giunchette R.C., Paixão T.A. & Santos R.L. 2020. Brucella ovis mutant in ABC transporter protects against Brucella canis infection in mice and it is safe for dogs. Plos One, 15, 4, 1 – 20. https://doi.org/10.1371/journal.pone.0231893.
Fornefett J., Krause J., Klose K., Fingas F., Hassert R., Benga L., Grunwald T., Müller U., Schrödl W. & Baums C.G. 2018. Comparative analysis of humoral immune responses and pathologies of BALB/c and C57BL/6 wildtype mice experimentally infected with a highly virulent Rodentibacter pneumotropicus (Pasteurella pneumotropica) strain. BMC Microbiology, 18, 1-11. https://doi.org/10.1186/s12866-018-1186-8 .
George M. & Abraham T.E. 2006. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan—a review, J Control Release, 114, 1, 1–14. https://doi.org/10.1016/j.jconrel.2006.04.017.
Golshani M., Amani M., Siadat S.D., Nejati-Moheimani M., Arsang A. & Bouzari S. 2018. Comparison of the protective immunity elicited by a Brucella cocktail protein vaccine (rL7/L12+rTOmp31+rSOmp2b) in two different adjuvant formulations in BALB/c mice. Mol Immunol, 103, 306 - 311. https://doi.org/10.1016/j.molimm.2018.10.002.
Halimi M., Alishahi M., Abbaspour M.R., Ghorbanpoor M. & Tabandeh M.R. 2019. Valuable method for production of oral vaccine by using alginate and chitosan against Lactococcus garvieae/Streptococcus iniae in rainbow trout (Oncorhynchus mykiss). Fish Shellfish Immunol, 90, 431 - 439. https://doi.org/10.1016/j.fsi.2019.05.020.
Heffernan M.J., Zaharoff D.A., Fallon J.K., Schlom J. & Greiner J.W. 2011. In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials, 32, 926–932. https://doi.org/10.1016/j.biomaterials.2010.09.058.
Kashem S.W., Haniffa M. & Kaplan D.H. 2017. Antigen-presenting cells in the skin. Annu Rev Immunol, 35, 469 – 499. https://doi.org/10.1146/annurev-immunol-051116-052215.
Kesarwani A., Sahu P., Jain K., Sinha P., Mohan K.V., Nagpal P.S., Singh S., Zaidi R., Nagarajan P. & Upadhyay P. 2021. The safety and efficacy of BCG encapsulated alginate particle (BEAP) against M.tb H37Rv infection in Macaca mulatta: a pilot study. Sci Rep, 11, 3049. https://doi.org/10.1038/s41598-021-82614-5.
Klouda L. & Mikos A.G. 2008. Thermoresponsive hydrogels in biomedical applications. Eur J Pharm Biopharm, 68, 1, 34 - 45. https://doi.org/10.1016/j.ejpb.2007.02.025.
Kojarunchitt T., Baldursdottir S., Dong Y-D., Boyd B.J., Rades T. & Hook S. 2015. Modified thermoresponsive poloxamer 407 and chitosan sol–gels as potential sustained-release vaccine delivery systems. Eur J Pharm Biopharm, 89, 74 - 81. https://doi.org/10.1016/j.ejpb.2014.11.026.
Moreno E. 2021. The one-hundred-year journey of the genus Brucella (Meyer and Shaw 1920). FEMS Microbiol Rev, 45, 1, 045. https://doi.org/10.1093/femsre/fuaa045.
Murphy E.A., Sathiyaseelan J., Parent M.A., Zou B. & Baldwin C.L 2001. Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology, 103, 4, 511-518. https://doi.org/10.1046/j.1365-2567.2001.01258.x.
Onuigbo E., Iseghohimhen J., Chah K., Gyang M. & Attama A. 2018. Chitosan/alginate microparticles for the oral delivery of fowl typhoid vaccine: Innate and acquired immunity. Vaccine, 36, 33, 4973 - 4978. https://doi.org/10.1016/j.vaccine.2018.05.087.
Powers E.G., Nash P.B., Rhyan J.C., Yoder C.A. & Miller L.A. 2007. Comparison of immune and adverse effects induced by AdjuVac and Freund’s complete adjuvant in New Zealand white rabbits (Oryctolagus cuniculus). Lab Anim, 36, 9, 51- 58. https://doi.org/10.1038/laban1007-51.
Rahaiee S., Shojaosadati S.A., Hashemi M., Moini S. & Razavi S.H. 2015. Improvement of crocin stability by biodegradeble nanoparticles of chitosan-alginate. Int J Biol Macromol, 79, 423 - 432. https://doi.org/10.1016/j.ijbiomac.2015.04.041.
Rice-Ficht A.C., Arenas-Gamboa A.M., Kahl-Mcdonagh M.M. & Ficht T.A. 2010. A polymeric particle in vaccine delivery. Curr Opin Microbiol, 13, 106 – 112. https://doi.org/10.1016/j.mib.2009.12.001.
Rocha C.E.V., Silva M.F., Guedes A.C.B., Carvalho T.P., Eckstein E., Ribeiro N.Q., Santos D.A., Melo M.M., Araújo M.S.S., Martins-Filho O.A., Santos R.L. & Paixão T.A. 2021. Alginate-chitosan microcapsules improve vaccine potential of gamma-irradiated Listeria monocytogenes against listeriosis in murine model. Int J Biol Macromol, 10, 176, 567 – 577. https://doi.org/10.1016/j.ijbiomac.2021.02.056.
Sadeghi Z., Fasihi-Ramandi M. & Bouzari S. 2019. Evaluation of immunogenicity of novel multi-epitope subunit vaccines in combination with poly I:C against Brucella melitensis and Brucella abortus infection. Int Immunopharmacol, 75, 105829. https://doi.org/10.1016/j.intimp.2019.105829.
Shakya A.K. & Nandakumar K.S. 2013. Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases. J R Soc Interface, 10, 79, 20120536. https://doi.org/10.1098/rsif.2012.0536.
Silva A.P.C., Macêdo A.A., Silva T.M.A., Ximenes L.C.A., Brandão H.M., Paixão T.A. & Santos R.L. 2015 (b) Protection provided by an encapsulated live attenuated abcBA strain of Brucella ovis against experimental challenge in a murine model. Clin Vaccine Immunol, 22, 7,789 – 797. https://doi.org/10.1128/cvi.00191-15.
Silva A.P., Macêdo A.A., Costa L.F., Turchetti A.P., Bull V., Pessoa M.S., Araújo M.S.S., Nascimento E.F., Martins-Filho O.A., Paixão T.A. & Santos R.L. 2013. Brucella ovis lacking a species-specific putative ATP-binding cassette transporter is attenuated but immunogenic in rams. Vet Microbiol, 167, 3-4, 546-53. https://doi.org/10.1016/j.vetmic.2013.09.003.
Silva A.P.C., Macêdo A.A., Costa L.F., Rocha C.E., Garcia L.N.N., Farias J.R.D., Gomes P.P.R., Teixeira G.C., Fonseca K.W.J., Maia A.R.F., Neves G.G., Romão E.L., Silva T.M.A., Mol J.P.S., Oliveira R.M., Araújo M.S.S., Nascimento E.F., Martins-Filho O.A., Brandão H.M., Paixão T.A. & Santos R.L. 2015 (a). Encapsulated Brucella ovis lacking a putative ATP-binding cassette transporter (ΔabcBA) protects against wild type Brucella ovis in Rams. Plos One, 10, e0136865. https://doi.org/10.1371/journal.pone.0136865.
Silva T.M.A., Mol J.P.S., Winter M.G., Atluri V., Xavier M.N., Pires S.F., Paixão T.A., Andrade H.M., Santos R.L. & Tsolis R.M. 2014. The predicted ABC transporter AbcEDCBA is required for type IV secretion system expression and lysosomal evasion by Brucella ovis. Plos One, 9, 12, e114532. https://doi.org/10.1371/journal.pone.0114532.
Silva T.M.A., Paixão T.A., Costa E.A., Xavier M.N., Sá J.C., Moustacas V.S., den Hartigh A.B., Carvalho Neta A.V., Oliveira S.C., Tsolis R. & Santos R.L. 2011. Putative ATP-binding cassette transporter is essential for Brucella ovis pathogenesis in mice. Infect Immun, 79, 1706 – 1717. https://dx.doi.org/10.1128%2FIAI.01109-10.
Stills Jr H.F. 2005. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. Ilar J, 46, 3, 280 - 293. https://doi.org/10.1093/ilar.46.3.280.
Windsor P.A., Bush R., Links I. & Eppleston J. 2005. Injury caused by self-inoculation with a vaccine of a Freund's complete adjuvant nature (Gudair) used for control of ovine paratuberculosis. Aust Vet J, 83, 4, 216 - 220. https://doi.org/10.1111/j.1751-0813.2005.tb11654.x.
Windsor P.A. & Eppleston J. 2006. Lesions in sheep following administration of a vaccine of a Freund's complete adjuvant nature used in the control of ovine paratuberculosis. N Z Vet J, 54, 5, 237 - 241. https://doi.org/10.1080/00480169.2006.36704.
